Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
What I am trying to establish is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
Not looking for reassurance. Looking for the part I have got wrong.
zoe_NC said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
My labs after 6 months on glycaemic control: A1C 5.1%, fasting glucose 76 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 6.7% and fasting glucose was 111 mg/dL. The improvement has been dramatic and consistent.
JennaRN said:My labs after 6 months on glycaemic control: A1C 5.1%, fasting glucose 76 mg/dL, fasting insulin 5 uIU/mL.
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:
| Biomarker | Association | Evidence Level |
|---|---|---|
| Baseline BMI | Higher BMI → greater absolute weight loss | Strong |
| Fasting insulin | Higher insulin → better response | Moderate |
| GLP1R gene variants | rs6923761 → variable response | Preliminary |
| Baseline hsCRP | Higher CRP → greater CV benefit | Moderate |
| Early weight loss (4 wk) | ≥3% at 4 wks → strong predictor of ≥10% at 68 wks | Strong |
The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardszoe_NC said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Adding a me-too, because a thread of one person's experience is not much use.
Clinical perspective, offered as context rather than as advice.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 117 | 99 | 89 | 83 |
| Insulin (fasting) | 23 | 13 | 9 | 6 |
| HOMA-IR | 5.5 | 3.8 | 1.7 | 1.1 |
| Uric Acid | 8.5 | 6.7 | 5.6 | 4.8 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.